Dr. Eran Eden, PhD

Co-founder and CEO, Board of Directors

Eran has been the CEO of MeMed since its inception in 2009, leading it from an idea to a rapidly growing company. He has 15 years of combined business and academic experience pioneering the development of cutting-edge multidisciplinary technologies that synergize data-science & machine learning, molecular biology and clinical applications. Eran co-founded several highly funded international consortia (e.g., Tailored-Treatment and Respiratory-ImmunoDx), the mission of which is to develop, clinically validate and commercialize novel technologies for diagnosing patients with infectious diseases and inflammatory disorders. He holds a B.Sc. in Computer Engineering, B.A. in Biology, and M.Sc. in Computer Science (all Cum Laude) from the Technion, Israel Institute of Technology, and a Ph.D. in Systems Biology from the Weizmann Institute of Science, where he was also a lecturer of Data Mining. Eran is co-author of over 90 granted patents and pending applications and over 20 peer-reviewed publications and is the recipient of multiple awards including the prestigious GE and Science Prize for Promising Life Scientists.


Dr. Kfir Oved, PhD

Co-Founder, CTO  and Chairman of Board of Directors

Kfir has over 15 years of combined industry and academic experience, leading interdisciplinary and multicultural teams combining Applied Immunology, Biochemistry, Engineering, Big Data, and Industrial Design, in multiple clinical applications. Kfir co-founded MeMed Dx and serves as its CTO and Chairman of the Board, where he led the development and clinical validation of the entire MeMed technology suite including the MeMed BV™ technology, and the MeMed Key™ Point of care platform, from an initial concept to development completion. He holds a B.A. in Biology (Summa Cum Laude), B.Sc. in Medicine (Magna Cum Laude), Ph.D. in Molecular Immunology, and 6 years training at the Technion-Institute of Technology School of Medicine. He is the co-author of 83 granted and pending patents, the author of 16 peer-reviewed publications, and the recipient of multiple research excellence awards, including the prestigious Gutwirth Excellence award and the Wolf Award for research students, and was listed as one of the top 25 voices in Precision Medicine for 2019.

Idan Danenberg

Chief Operating Officer

Idan has over 15 years of leadership experience in international operations and supply chain, lean manufacturing and service in the pharmaceutical and medical device industries. Prior to joining MeMed’s team, Idan led the global operations, supply chain and service as COO for Degania Medical, a world leader for disposable catheters, cardiovascular catheters and custom procedure trays, with 6 manufacturing plants and 3 logistics sites globally. Prior to that, Idan led the operations of the Israeli and Canadian sites as VP Operations for Taro Pharmaceuticals (NYSE: TARO), a multinational manufacturer of OTC and Rx oral solid dosage, semi-solid and liquid formulations. Idan holds a B.Sc. in Biotechnology and Food Engineering from the Technion – Israel Institute of Technology, and an MBA from Haifa University.


Dr. Frederic Sweeney, PhD

Chief Business Development Officer

Fred has extensive experience in the healthcare industry with senior leadership roles leading strategy and corporate development in both small and large organizations. Prior to joining MeMed, Fred served a dual role of Entrepreneur-In-Residence for Versant Ventures, a global venture capital firm, and Chief Business Officer of Northern Biologics, a developer of first-in-class immuno-oncology products. Prior to this, Fred served as Vice President of Corporate Development and Head of Strategic Financing at bioMérieux, a world leader in in-vitro diagnostic, where he led all aspects of the company strategic investments and partnerships. Before joining bioMérieux, Fred was Head of Business Development and Strategy at T2 Biosystems. During his tenure with the company, T2 Biosystems grew from a small venture-backed startup to a revenue-stage, Nasdaq-listed company that received FDA approval for blood tests that identify sepsis-causing pathogens without the wait for blood culture. A graduate of the Molecular and Medical Genetics Department and Terry Fox Scholar at the University of Toronto, Fred completed a Ph.D. focused on DNA repair, signal transduction and structural biology. He is also an adjunct professor at the University of Toronto, where he teaches a graduate level course on entrepreneurship in life sciences.

Dr. Tanya Gottlieb, PhD

VP of Scientific Affairs

Tanya has over 20 years of experience in academia and biotech, specializing in building and cultivating international collaborations and securing non-dilutive financing. Before joining MeMed, Tanya was Director of Business Development at BiondVax Pharmaceuticals Ltd (NASDAQ: BVXV), an innovative start-up developing a universal flu vaccine, where she initiated collaborations with the National Institute of Health (US) and European Commission. Prior to that, Tanya served as an independent consultant for key opinion leaders in Israel and Europe, helping to maximize their impact in the field and win awards. Tanya conducted her postdoctoral research at the Weizmann Institute of Science, Israel and the Fred Hutchinson Cancer Research Center in Seattle, WA, USA. Tanya holds a B.A. in Natural Sciences and Ph.D. from Cambridge University, UK. and an MBA from the Technion, Israel. She is the co-author of over 20 peer reviewed publications and the recipient of multiple awards, including the prestigious Royal Society (UK)-Israel Academy Fellowship.

Ofer Halbreich 

VP Commercial and Corporate Development

Ofer has over 15 years of experience in global operations, business development, strategic planning and M&As. Prior to joining MeMed, Ofer led the global operations of MediaMind Technologies Inc. Prior to that, he was the COO of Neuronix Medical, a medical device company in the field of Alzheimer’s treatment. Before that, Ofer acted as VP of Business Development & Legal Counsel for Office Depot (Israel) and served as commercial lawyer for prominent Israeli law firms. Ofer holds an LLB from the Hebrew University and an MBA (Finance) from the Interdisciplinary Center in Herzliya.

Dr. Efrat Hartog-David, PhD

Director of Regulatory Affairs and Quality Assurance

Efrat has over a decade of experience in Quality Assurance, Clinical and Regulatory Affairs. She has managed product lifecycle quality and regulatory submissions for clearances of numerous medical devices in the US, EU, China, and rest of the world. Before joining MeMed, Efrat was Regulatory Affairs Manager at GE Healthcare, responsible for leading and executing the global regulatory strategy for the Nuclear Medicine business. As part of her role at GE Healthcare she led a team responsible for providing leadership and guidance on global compliance, developing global regulatory strategies and plans, and preparing regulatory submissions and worldwide registrations. Efrat has also served as Regulatory Affairs specialist at Philips Healthcare, where she was the regulatory lead for programs aimed at introduction of new product, and played a key role in internal and external audits. Prior to that, Efrat served as a consultant for a wide range of medical device companies, focusing on clinical study design, quality system management, and regulatory strategy development and execution. Efrat holds a B.Sc. and Ph.D. in Biotechnology and Food Engineering from the Technion, Haifa, Israel.

Kfir Emmer

VP Finance

Kfir has more than a decade experience in the fields of finance and accounting. Prior to joining MeMed’s team, Kfir, previously acted as the Financial Controller at Viola Ventures, Israel's leading VC firm with over $1.3 billion assets under management. Prior to that, Kfir held the position of senior auditor at PWC, specializing in auditing biotech companies. Kfir has extensive experience in private placements, cash management, strategic planning, deal analysis, accounting and financial operations management. Kfir is a Certified Public Accountant and also holds a B.A. in Accounting and Economics and an MBA (Financial Management), both from the Tel Aviv University.

Hila Hershkovitz


Hila has over 18 years of experience in senior HR leadership roles with fast growing tech companies at various stages. Prior to joining MeMed Hila served as HR Business Partner for EMEA region at Amdocs (NASDAQ: DOX), and for the Operation Innovation Unit where she oversaw all global HR activities. Prior to that Hila worked with startups (e.g. Flash Networks and Correlsense) and was responsible for the global human resources strategy. Hila holds a B.A. in Social Work from Tel Aviv University and an MBA from Bar-Ilan University.

Adee Mor

VP Marketing

Adee has over 18 years of extensive experience in healthcare and high-tech industries, in executive marketing, commercial and financial roles, in global corporates, local subsidiaries and entrepreneurial ventures. She previously served in marketing and commercial leadership roles at Teva Pharmaceuticals Ltd (NASDAQ: TEVA), as the head of marketing and business Initiatives, generics business, Chief of Staff to the President and CEO, EMIA & APAC and CFO, APAC & China, successfully leading commercialization of numerous medical devices, generic drugs and innovative solutions. Before her tenure at Teva, Adee served in various financial senior roles in high tech global corporates. Adee brings vast experience in market entries, product launch, building and developing growth strategies in complex global environments. Adee earned her Bachelor of Science in Economy and Corporate communications and her executive MBA (Magna cum laude), both from the Hebrew university of Jerusalem.

Dr. Oren Zarchin, PhD


Oren is a highly experienced leader of Product Development in global corporations, with more than 20 years of business and academic experience in the medical and semiconductors industries. In his latest role, Oren served as VP Product Development and executive management at Mazor Robotics LTD. Following Mazor's acquisition by Medtronic PLC. he served as VP Product development at Medtronic, leading R&D and Product Management. Prior to Medtronic Oren held various leadership positions at Philips Healthcare where he led multi-disciplinary R&D teams and product platforms in the US and Israel. Oren has a Ph.D. in Physics from the Weizmann institute of Science, M.Sc. (summa cum laude) in Physics and B.Sc. (cum laude) in Computer Science and Physics from Tel-Aviv University. He holds 15 patents and is the co-author on multiple publications.

Board of Directors

Mr. Patrick F. Terry

Mr. Terry is a social entrepreneur who has co-founded a dozen life science organizations in the last 20 years and has been called the godfather of applied genomics and personalized medicine. The organizations co-founded by Mr. Terry include innovative philanthropic, research, and commercial organizations based on the life sciences, applied technology, and social-network theory. In 2000, he co-founded Genomic Health, Inc. (NASDAQ: GHDX), a pioneering personalized medicine company. Mr. Terry has been involved in shepherding multiple biotechnology products through commercial development to clinical delivery all over the world. He has received many honors and awards in the business and scientific communities internationally. He has dedicated his career to advancing a patient-centered perspective in research, product development, and translational medicine. He is active internationally with strategic management and financing of stratified medicine companies for numerous clinical indications and technologies. 

Mr. Hanina Brandes

Mr. Brandes is the founding and managing partner of Naschitz-Brandes, one of the leading law firms in Israel. Mr. Brandes has advised on some of Israel’s largest and most complex international commercial transactions. His clients include Israel’s leading public and private companies. Mr. Brandes is the chairman of the High-tech committee of the Israeli Bar, a member of the Board of Governors of Tel-Aviv University, as well as a member of the Board of Trustees and the Board of Directors of Tel-Aviv Museum of Art.

Mr. Patrick Zhang

Patrick Zhang is an investor at Horizons Ventures, where he primarily covers biotechnology, healthcare and fintech investments, and manages related portfolio companies for Horizons. He was trained as a chemical engineer and worked in a variety of organizations across industries including power utilities, financial services and investment management. Prior to Horizons, Patrick was an investment banker with Morgan Stanley providing financial advisory services on capital raising and cross-border M&A to his clients. Mr. Zhang received his BS degree in Chemical Engineering from UCLA and MBA from Columbia Business School.

Mr. Shmuel (Mooly) Eden

Mr. Eden is a former Senior Vice President at Intel Corporation, and President of Intel Israel. In this capacity, Mr. Eden led the PC Client Group, Intel’s largest product group with over $35 billion annual revenues in 2011, where he oversaw the platform planning, architecture, enabling, and marketing of Intel`s PC solutions for the desktop and mobile computing segments. In his 30 years at Intel, Mr. Eden held many management and technical positions in microprocessor design. Mr. Eden is considered one of the leaders of the mobile PC revolution. In 2010, Mr. Eden was ranked 26th on The Fast Company`s list of the world`s 100 most creative people. In 2012, Mr. Eden was named one of the world`s 10 most brilliant technological minds on the Fortune 500 list. On top of serving on Memed BOD, Mr Eden is the chairman of the Executive committee of the University of Haifa, and he consults and serves on the board of several startups.

Mr. Peter Neustadter

Mr Neustadter was an early investor and consultant to Mobileye and served on its Board of Directors as the non-executive presiding officer until its sale to Intel in 2017. Peter S Neustadter was President and CEO of Durawool Inc., which developed and became the leading manufacturer of non-asbestos fibers for the automotive industry. He is currently Managing Director of Iat holdings Llc which invests in Israeli automotive technologies and International Automotive Trading, a financial advisory company. Today he is active in several startups and philanthropic institutions.


Board of Advisors

Prof. Paul Feigin

Statistics  Advisor

Paul Feigin is Professor of Statistics and the Senior Executive VP of the Technion, Israel Institute of Technology. He is an authority on statistical design and analysis of genomic studies, and clinical studies. Prof. Feigin has served as a statistician regulatory consultant for many companies, working on clinical study protocol design and statistical analysis. He has extensive experience in strategic preparation for regulatory submission and communication with regulatory agencies and notified bodies. Prof. Feigin served as Dean of the Faculty of Industrial Engineering and Management at the Technion, as president of the Israel Statistical Association, and he is currently an elected fellow of the Institute of Mathematical Statistics and of the International Statistical Institute. Prof. Feigin published over 50 scientific papers and has been a visiting professor at world-class institutes including Berkeley, Cornell University, Stanford University and others. 

Dr. Louis Bont

Clinical Advisor

Dr. Bont, MD, PhD, is a Pediatrician Infectiologist at the University Medical Center Utrecht, The Netherlands. His research activities focus on viral respiratory tract infections, particularly RSV bronchiolitis. He leads the Utrecht RSV Research Group. Dr. Bont received several awards, including a European Society of Pediatric Infectious Diseases (ESPID) Fellowship Award. He has published 70 papers in peer-reviewed journals and is the chairman of the international Bronchiolitis Academy training program for pediatricians, the Global Expert Meeting on respiratory viruses (GEM) and the Training of Upcoming Leaders in Paediatric Sciences (TULIPS) in The Netherlands. He holds an ESPID membership. Dr. Bont earned his medical degree from the University of Amsterdam, The Netherlands and completed a residency in pediatrics at Victoria Hospital in Blackpool, United Kingdom; St. Antonius Hospital in Nieuwegein, The Netherlands; and Wilhelmina Children’s Hospital, University Medical Center in Utrecht, The Netherlands.

Prof. Itamar Shalit

Clinical Advisor

Prof. Shalit is an Associate Professor in Pediatrics, Sackler Faculty of Medicine, Tel-Aviv University and a world authority in Pediatric Infectious Diseases. Prof. Shalit served as the Director of the Infectious Diseases Unit and Director General of Schneider Children`s Hospital, tertiary care, referral pediatric center, for the entire state of Israel. He also served as the Director General of Carmel Hospital, the Chairman of the Israeli Society for Infectious Diseases, and as a member of the Scientific Advisory Boards of leading pharma and biotech companies including Bioline Rx, Teva Innovative Ventures, NasVax and Integra Ltd. Prof. Shalit is an active member of several national committees of the Israeli Ministry of Health among them the Advisory Board on Infectious Diseases and Immunization, Polio Eradication Committee, and the Epidemics Management Team. He was awarded the Certificate of Appreciation Declaration by the World Health Organization for outstanding efforts and success in poliomyelitis eradication in Israel. Prof. Shalit holds an MD from the Sackler School of Medicine, Tel-Aviv University and a MPA (Master in Public Administration) from the Kennedy School of Government at the Harvard University. He is the author of more than 90 peer reviewed scientific papers and currently serves as the CEO of the Galilee Biomedical Research Administration. 

Prof. Israel Potasman

Clinical Advisor

Prof. Potasman has been the Head of the Infectious Diseases Department at the Bnai-Zion Medical Center (BZMC), Haifa, for the past 22 years, and is a regional infectious disease consultant at Maccabi Health Services. He is a national authority on topics of travel medicine. Prof Potasman published over 120 scientific papers and reviews on a wide range of topics in infectious diseases and travel medicine. Prof. Potasman is a graduate of the Hebrew University, Hadassah Medical School, Jerusalem. He specialized in internal medicine at the BZMC, and in infectious diseases at Stanford University (laboratory of J.S. Remington). 

Prof. Zohar Yakhini

Scientific Advisor

Dr. Yakhini is a Professor of Computer Science at the Herzeliya Interdisciplinary Center and a Visiting Professor in the Computer Science Department at the Technion, Haifa. Dr Yakhini has been a Master Scientist at Agilent Laboratories until 2016, where he has led and mentored research and development work in the field of molecular measurement and bioinformatics. His group's current research mostly focuses on statistics, data analysis and machine learning techniques applied to molecular biology and to other domains. Dr. Yakhini has a publications h-index of 45 and is an inventor of 13 issued US patents.

Prof. Yoram Reiter

Scientific Advisor

Prof. Reiter is the former dean of the Faculty of Biology and the head of the Laboratory of Molecular Immunology at the Technion, Israel Institute of Technology. Prof. Reiter is a world leader in the isolation of human T-cell receptor-like (TCRL) molecules, with various applications in molecular immunology of cancer and infectious diseases. His work involves the development of novel immunotherapeutic approaches, as well as the study of molecular mechanisms in anti-tumor and anti-viral immunity. Prof. Reiter received his Ph.D. from the Department of Immunology at the Weizmann Institute of Science and subsequently spent five years at the National Cancer Institute (NCI) at the Laboratory of Molecular Biology headed by Dr. Ira Pastan, where he developed new approaches in antibody engineering. Prof. Reiter published over 100 scientific papers and reviews and holds 15 patents. He is the co-founder and CTO of Applied Immune Technology (AIT) Inc. and serves as an advisor to several pharmaceutical and biotechnology companies. 

Dr. Modi Segal

Dr. Segal is a seasoned businessman active in the high-tech and biotech industries and a philanthropist. He serves on the board of Governors of the Weizmann Institute of Science, was a senior executive of Texas Instruments and a co-founder and CTO of Libit Signal Processing, which was acquired by Texas Instruments in 1999 for $365 million. Dr. Segal holds a Ph.D. (with distinction) in electrical engineering from Tel Aviv University. 

Dr. Eli Opper

Dr. Opper brings over 45 years of experience in global R&D and business development in the high tech and biotech sectors. He is the former Chief Scientist of the Ministry of the Economy of Israel, a role he served from 2002 to 2010. He also served as the chairman of Eureka (2010-2011), a major pan-European R&D funding and coordination organization, and the chairman of BIRD foundation. Prior to that, Dr. Opper served as a venture partner at Giza Venture Capital from 2000 to 2002 and before that, he worked at Rafael for 27 years, where he held numerous roles including Chief of Staff and Corporate Vice President for R&D. Dr. Opper holds a B.Sc. and M.Sc. from the Technion, Israel Institute of Technology and Ph.D. in computer engineering from the University of Texas at Austin, TX. He published 14 papers in journals and conferences and over 50 internal papers at Rafael. 

Yahal Zilka 

Mr. Yahal Zilka brings many years of experience as an entrepreneur, mentor and executive. In addition to his knowledge of the communications and technology sectors, Mr. Zilka has worked closely with both the investment banking and venture capital communities. Mr. Zilka co-founded Magma Venture Partners and has positioned Magma as a major player in the New Media space. During his tenure as chairman and acting CEO of Phonetic Systems, a portfolio company of the Fund, Mr. Zilka led Magma’s first exit when Phonetic Systems was acquired by Nuance (NASDAQ: NUAN). Prior to Magma, Mr. Zilka served as CFO of VocalTec Communications from 1995 to 1999, where he was part of the team that pioneered VOIP and led the company from seed to its public offering on NASDAQ (NASDAQ: CALL). Mr. Zilka currently serves as Director on the boards of SightEra-Magisto, Valens Semiconductor and Indegy. Previously, Mr. Zilka was on the boards of Waze (acquired by Google, NASDAQ: GOOG), Onavo (acquired by Facebook, NASDAQ:FB), DesignArt Networks (acquired by Qualcomm, NASDAQ: QCOM) and Phonetic Systems (acquired by Nuance, NASDAQ: NUAN). Since 2009, Mr. Zilka has served as Chairman of the HTIA (now IATI) Annual Conference, Israel's most prestigious and comprehensive technology conference.